Immunome announces $138.1M cash estimate, commences public offering; updates pipeline and AL102 acquisition

Immunome Inc.

Preliminary cash, equivalents, and marketable securities of ~$138.1M as of Dec 31, 2023, subject to final close.
Underwritten public offering of common stock commenced; proceeds intended to fund pipeline and operations.
Signed asset purchase agreement with Ayala for AL102 (GSI) in desmoid tumors; expected close in late Q1 or early Q2 2024.
Pipeline: IND filings for IM-1021 (ROR1 ADC), IM-4320 (anti-IL-38), and FAP RLT all targeted for Q1 2025.
CEO Clay Siegall (former Seagen CEO) leads; management team includes former Morphimmune executives.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.